NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...
Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback